echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Chinese scholars discovered gastric cancer anti-tumor immune "super soldier" cells

    Chinese scholars discovered gastric cancer anti-tumor immune "super soldier" cells

    • Last Update: 2021-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network, May 27, after 3 years of research, Chinese medical experts have discovered and verified the "super soldier" against tumor cells in the gastric cancer microenvironment, providing a new model for the improvement of the prognosis prediction model of gastric cancer patients and the individualized choice of immunotherapy.
    direction.
     
    The research team of Professor Xu Jiejie, School of Basic Medicine, Fudan University, found that CXCR5+CD8+T cells can be used as a new prognostic marker and potential immunotherapy target for gastric cancer patients in a large sample of gastric cancer patients and four cohorts (from different clinical centers) And a guiding factor for individualized medication.
     
    Related research results were published on the 25th in the international academic journal "Nature" magazine "Nature Communications" ("Nature Communications").
     
    In an interview with reporters, Xu Jiejie introduced that the early symptoms of gastric cancer are not obvious, and many patients are already in the advanced stage when they are first diagnosed.
    Although standard radical gastric cancer surgery and postoperative chemotherapy can bring certain survival benefits to gastric cancer patients, the prognosis of most patients is still not optimistic.
    Therefore, it is of great significance to discover new markers of gastric cancer treatment response, so as to achieve precise medical treatment of gastric cancer patients.
     
    It is understood that in recent years, by intervening in the tumor immune microenvironment and the patient's immune system, achieving sustained anti-tumor effects has become an important means of treating advanced tumors.
    Xu Jiejie pointed out that exploring new immunotherapy targets to improve the quality of life of gastric cancer patients has become an important clinical problem that urgently needs to be resolved.
     
    The research team found that CXCR5+CD8+ T cell expression has an "immune brake" checkpoint molecule that is "particularly capable of fighting".
    The more cells of this group of "super fighters" indicate that the patient has a longer overall survival time, and confirms that the patient has a better response to postoperative adjuvant chemotherapy or chemotherapy combined with radiotherapy.
    Relevant conclusions have been confirmed in four cohort studies of gastric cancer patients.
    (Finish)
      Medical Network, May 27, after 3 years of research, Chinese medical experts have discovered and verified the "super soldier" against tumor cells in the gastric cancer microenvironment, providing a new model for the improvement of the prognosis prediction model of gastric cancer patients and the individualized choice of immunotherapy.
    direction.
     
      The research team of Professor Xu Jiejie, School of Basic Medicine, Fudan University, found that CXCR5+CD8+T cells can be used as a new prognostic marker and potential immunotherapy target for gastric cancer patients in a large sample of gastric cancer patients and four cohorts (from different clinical centers) And a guiding factor for individualized medication.
     
      Related research results were published on the 25th in the international academic journal "Nature" magazine "Nature Communications" ("Nature Communications").
     
      In an interview with reporters, Xu Jiejie introduced that the early symptoms of gastric cancer are not obvious, and many patients are already in the advanced stage when they are first diagnosed.
    Although standard radical gastric cancer surgery and postoperative chemotherapy can bring certain survival benefits to gastric cancer patients, the prognosis of most patients is still not optimistic.
    Therefore, it is of great significance to discover new markers of gastric cancer treatment response, so as to achieve precise medical treatment of gastric cancer patients.
     
      It is understood that in recent years, by intervening in the tumor immune microenvironment and the patient's immune system, achieving sustained anti-tumor effects has become an important means of treating advanced tumors.
    Xu Jiejie pointed out that exploring new immunotherapy targets to improve the quality of life of gastric cancer patients has become an important clinical problem that urgently needs to be resolved.
     
      The research team found that CXCR5+CD8+ T cell expression has an "immune brake" checkpoint molecule that is "particularly capable of fighting".
    The more cells of this group of "super fighters" indicate that the patient has a longer overall survival time, and confirms that the patient has a better response to postoperative adjuvant chemotherapy or chemotherapy combined with radiotherapy.
    Relevant conclusions have been confirmed in four cohort studies of gastric cancer patients.
    (Finish)
      Medical Network, May 27, after 3 years of research, Chinese medical experts have discovered and verified the "super soldier" against tumor cells in the gastric cancer microenvironment, providing a new model for the improvement of the prognosis prediction model of gastric cancer patients and the individualized choice of immunotherapy.
    direction.
     
      The research team of Professor Xu Jiejie, School of Basic Medicine, Fudan University, found that CXCR5+CD8+T cells can be used as a new prognostic marker and potential immunotherapy target for gastric cancer patients in a large sample of gastric cancer patients and four cohorts (from different clinical centers) And a guiding factor for individualized medication.
     
      Related research results were published on the 25th in the international academic journal "Nature" magazine "Nature Communications" ("Nature Communications").
     
      In an interview with reporters, Xu Jiejie introduced that the early symptoms of gastric cancer are not obvious, and many patients are already in the advanced stage when they are first diagnosed.
    Although standard radical gastric cancer surgery and postoperative chemotherapy can bring certain survival benefits to gastric cancer patients, the prognosis of most patients is still not optimistic.
    Therefore, it is of great significance to discover new markers of gastric cancer treatment response, so as to achieve precise medical treatment of gastric cancer patients.
     
      It is understood that in recent years, by intervening in the tumor immune microenvironment and the patient's immune system, achieving sustained anti-tumor effects has become an important means of treating advanced tumors.
    Xu Jiejie pointed out that exploring new immunotherapy targets to improve the quality of life of gastric cancer patients has become an important clinical problem that urgently needs to be resolved.
    Tumor tumor tumor
     
      The research team found that CXCR5+CD8+ T cell expression has an "immune brake" checkpoint molecule that is "particularly capable of fighting".
    The more cells of this group of "super fighters" indicate that the patient has a longer overall survival time, and confirms that the patient has a better response to postoperative adjuvant chemotherapy or chemotherapy combined with radiotherapy.
    Relevant conclusions have been confirmed in four cohort studies of gastric cancer patients.
    (Finish)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.